Milk Thistle (Silybum marianum)
Milk thistle (Silybum marianum) is a flowering plant whose mature seeds have been used in European herbal medicine for "liver complaints" since classical Greek and Roman times. Sold widely in UK pharmacies and health-food shops, milk thistle is one of the most-marketed liver-support botanicals — but the gap between consumer marketing language ("liver cleanse", "natural liver support") and the actual UK regulatory + clinical evidence is genuinely large. The UK regulatory tier matters. MHRA-registered Traditional Herbal Medicinal Product (THR) milk-thistle preparations are registered for "the relief of symptoms associated with occasional overindulgence in food or drink such as indigestion and upset stomach" — a DIGESTIVE symptomatic indication, NOT a liver-disease treatment claim. The common online framing around liver-cleansing supplementation is non-regulated UK marketing language. EFSA's evaluation of liver-related claims for milk thistle is on hold; UK food-supplement-tier milk thistle cannot make UK liver claims. The clinical evidence is mixed. The Li 2024 Ann Hepatol systematic review + meta-analysis (PMID 38579127, 26 RCTs n=2,375) reported silymarin (the active flavonolignan complex in milk thistle) significantly reduced total cholesterol, triglycerides, LDL-C, ALT, AST, and fatty liver scores in patients with NAFLD / NASH — a contemporary supportive signal. Earlier Cochrane reviews (Rambaldi 2007) on milk thistle in chronic liver disease found insufficient evidence to support clinical use; trial heterogeneity has been substantial. UK NICE NG49 (NAFLD) pathway uses weight management + metabolic-syndrome control and does NOT include milk thistle. Three practical things to know: 1. <strong>Standardisation matters.</strong> The trial- evidenced material is silymarin-standardised extract (≥70-80% silymarin, with silybin / silibinin declared in better- controlled preparations). Whole-seed milk thistle powder at the same milligram weight delivers substantially less silymarin and is NOT trial-comparable. 2. <strong>Asteraceae allergy is a hard contraindication.</strong> Same plant family as ragweed, daisy, mugwort, marigold, chamomile, echinacea, feverfew. Severe reactions reported. 3. <strong>If you have diagnosed liver disease, talk to your GP or hepatology team FIRST.</strong> UK NICE pathway is the foundation; milk thistle is an optional adjunct conversation, not a replacement for medical care. Camden Medicals does NOT currently retail single-active milk- thistle SKUs. For UK consumers researching this space: a UK MHRA THR-registered silymarin-standardised product is the controlled-quality route.
Camden Medicals editorial · Last reviewed 12 May 2026 · Next review May 2027
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Botanical
- Typical daily dose
- UK MHRA THR-registered milk thistle preparations typically deliver 80-200 mg/serving of standardised seed extract at 70-80% silymarin (i.e., 56-160 mg silymarin per serving). Cochrane review trial-pool dose range was 280-800 mg/day silymarin. Phytosome / phospholipid-bound silybin preparations (Siliphos®, IdB 1016) deliver substantially better bioavailability and use lower silybin doses (140-280 mg/day).
- Top use evidence
- Strong
On this page
What it is
Milk thistle (Silybum marianum) is a thistle-like herbaceous biennial in the Asteraceae family, native to southern Europe and the Mediterranean. The plant is named for the milky-white veining on the leaves and the white sap that exudes when leaves are broken. The mature seed (achene) — borne in the prickly purple flower heads at the end of the second year of growth — is the medicinal part.
The constituents most associated with biological activity are:
- Silymarin — a complex of flavonolignans, the principal characterised actives in milk thistle. The complex includes silybin A, silybin B (silibinin is the racemic mixture of silybin A and silybin B), isosilybin A, isosilybin B, silychristin, silydianin, and several minor flavonolignans. Silybin (silibinin) is the most-studied single component and is often the standardisation marker in trial-grade extracts.
- Other flavonoids — taxifolin, quercetin, kaempferol — present at low concentrations.
- Lipids and tocopherols — milk thistle seed is approximately 25% lipid by weight (linoleic acid, oleic acid, palmitic acid) plus tocopherols.
UK supplement preparations span:
- Standardised seed extract capsules at 80-200 mg/serving providing 70-80% silymarin (i.e., 56-160 mg silymarin per serving), often labelled as "silymarin" content rather than total extract.
- Whole-seed milk thistle powder at 500-1000 mg/serving — substantially lower silymarin content per serving than the standardised extract.
- Liquid tincture preparations.
- Phytosome / phospholipid-bound silybin preparations (Siliphos®, IdB 1016) with documented improved bioavailability over standardised extract — the most-studied trial-grade material in chronic liver disease RCTs.
UK MHRA Traditional Herbal Registration (THR) products contain standardised extracts and carry the THR XXXXX/XXXX licence number on the pack. The THR scheme registers products on safety, quality, and traditional use — not on efficacy evidence. THR registered indication wording for UK milk thistle is "relief of symptoms associated with occasional overindulgence in food or drink such as indigestion and upset stomach" — a digestive symptomatic-relief framing, not a liver-disease treatment framing.
Generic milk thistle seed powder at the same milligram as a standardised extract delivers a small fraction of the silymarin content; trial-comparable supplementation requires a standardised extract or a phytosome preparation with silymarin / silybin percentage declared.
At a glance
- UK MHRA THR-registered (in registered products) for "symptoms associated with occasional overindulgence in food or drink such as indigestion and upset stomach" — a DIGESTIVE symptomatic-relief indication, NOT a liver-disease treatment indication. EFSA's evaluation of milk thistle liver and digestive claims is on hold, so food-supplement-tier milk thistle carries no authorised UK health claim.
- Evidence is mixed. A contemporary meta-analysis (Li 2024, Ann Hepatol, PMID 38579127; 26 RCTs, n=2,375 in NAFLD/NASH) reported reductions in lipid and liver-enzyme markers, but UK NICE NG49 (NAFLD) does not include milk thistle, and older Cochrane review evidence in chronic liver disease was insufficient to support clinical use.
- Standardisation is critical: the trial-grade material is a standardised silymarin extract (70-80% silymarin, the silybin/silibinin flavonolignan complex). Whole-seed milk thistle powder at the same milligram weight delivers a substantially lower silymarin dose and is not trial-comparable.
- Critical contraindication: Asteraceae plant-family allergy (ragweed, daisy, mugwort, marigold, chamomile, echinacea, feverfew) — severe reactions reported. Avoid concentrated extracts in pregnancy and breastfeeding. If you have diagnosed liver disease, talk to your GP or hepatology team before taking milk thistle.
What people use it for
Adults wanting symptomatic relief of occasional indigestion or stomach upset after rich food or drink
UK MHRA THR-registered milk thistle preparations may be marketed for "the relief of symptoms associated with occasional overindulgence in food or drink such as indigestion and upset stomach" — a digestive symptomatic-relief indication, NOT a liver-protection or liver-disease treatment indication. Mild bile-flow effect underpins the digestive use. UK NICE pathway for dyspepsia (CKS Dyspepsia) is lifestyle adjustment + antacid + (where indicated) Helicobacter pylori screen-and-eradication regimen. [11]
Some evidenceLimitedAdults considering milk thistle for diagnosed chronic liver disease (alcoholic liver disease, hepatitis B / C, NAFLD)
Cochrane review evidence is insufficient to support clinical use of milk thistle in chronic liver disease. UK NHS pathways for chronic liver disease are condition-specific (alcohol-cessation services for alcoholic liver disease, antiviral therapy for hepatitis B / C, weight management and metabolic-syndrome control for NAFLD). Self-supplementing milk thistle for diagnosed chronic liver disease is not the NHS-recognised pathway. Talk to the hepatology team managing your condition. [7,4]
Popular, not provenInsufficientAdults considering milk thistle for "liver cleanse" or cleansing-marketing claims
There is no UK-recognised pathway and no UK-authorised health claim for "liver cleanse" or cleansing-marketing positioning. The liver, kidneys, and lymphatic system are the body's working clearance routes; cleansing-marketing terms are non-regulated with no defined biomarker or clinical endpoint. UK marketing of milk thistle as a cleansing-tier product is outside both UK rules and trial-evidence boundaries.
Popular, not provenInsufficientAdults with diagnosed Asteraceae allergy
AVOID milk thistle. Cross-reactivity with the Asteraceae plant family (ragweed, daisy, mugwort, marigold, chamomile, echinacea, feverfew) is the principal allergy concern. Severe reactions including anaphylaxis have been reported. [3]
Some evidenceStrongAdults on prescribed medication metabolised by CYP enzymes
Modest in vitro signals exist for silymarin inhibition of CYP2C9, CYP3A4, and UGT enzymes. Clinical relevance at standard supplement doses is debated and likely modest, but disclose any milk thistle use to the prescribing pharmacist or GP — particularly if you take warfarin, an oral diabetes medicine, certain statins, or a chemotherapy drug. [11]
Some evidenceLimitedPregnant or breastfeeding women, or women trying to conceive
Avoid concentrated supplement extracts. Safety in pregnancy and lactation is insufficient; THR product literature lists pregnancy as a contraindication. [12]
Some evidenceLimited
How it works
Silymarin's hepatoprotective mechanism (in cell-biology and animal-model preparations) is multifactorial:
Antioxidant activity. Silymarin scavenges reactive oxygen species and increases intracellular glutathione levels in hepatocytes. The mechanism is modest at oral food-supplement doses — silybin's oral bioavailability from standardised extract is low (around 20-50%), with first-pass metabolism producing glucuronide and sulphate conjugates that recirculate via enterohepatic circulation. Phytosome preparations (silybin bound to phosphatidylcholine) improve oral bioavailability several-fold and are the trial-grade material in most chronic liver disease RCTs.
Anti-inflammatory activity. Silymarin inhibits NF-κB signalling and reduces inflammatory cytokine release (TNF-α, IL-6, IL-1β) in hepatic Kupffer cells in cell-biology assays. Translation to clinical anti-inflammatory effect on hepatic inflammation in human chronic liver disease has been the subject of multiple RCTs with mixed results.
Membrane stabilisation. Silybin appears to stabilise hepatocyte cell membranes against toxin-induced damage in cell-biology assays. The mechanism underpins the use of intravenous silibinin (Legalon SIL®) as an adjunct in death-cap mushroom (Amanita phalloides) poisoning — a hospital-pharmacy clinical indication where silibinin reduces α-amanitin uptake into hepatocytes via OATP1B1 / OATP1B3 transporter inhibition. The intravenous indication is NOT a food-supplement context and the same therapeutic effect is not delivered by oral milk-thistle supplementation.
Stellate-cell modulation. Silymarin reduces hepatic stellate cell activation and collagen deposition in animal-model fibrosis assays. The translation to clinical anti-fibrotic effect in human chronic liver disease has not been consistently demonstrated in RCTs.
Mild bile-flow effect. Silymarin has modest cholagogue (bile-flow-promoting) activity, the mechanistic basis for the THR-registered "occasional overindulgence in food or drink, indigestion and upset stomach" digestive indication.
The clinical-trial picture in chronic liver disease has been disappointing relative to the cell-biology and animal-model evidence. Cochrane review (Rambaldi 2007) concluded that the evidence base for milk thistle in alcoholic liver disease and hepatitis B/C was "insufficient evidence to support clinical use" — trial sizes small, durations short, and outcome measures heterogeneous. Subsequent RCTs in non-alcoholic fatty liver disease (NAFLD) and hepatitis C have produced inconsistent results.
The "liver cleanse" cleansing-marketing framing in popular marketing is NOT consistent with the trial evidence or with the THR registration scope. Milk thistle does not clear toxins from the body through any defined mechanism; the liver, kidneys, and lymphatic system are the body's working clearance routes. UK marketing language using "liver cleanse", "liver flush", or cleansing-marketing terms is non-regulated and not supported by trial evidence.
Common myths
Myth""Milk thistle detoxes / cleanses the liver.""
RealityThere is no UK-recognised pathway and no UK-authorised health claim for cleansing-marketing positioning of milk thistle. The liver, kidneys, and lymphatic system are the body''s working clearance routes; cleansing-marketing terms are non-regulated with no defined biomarker or clinical endpoint. UK MHRA THR registration for milk thistle is for digestive- discomfort symptomatic relief, not for liver clearance or liver-toxin removal.
Myth""Milk thistle protects your liver from alcohol.""
RealityCochrane review evidence does not support milk thistle as a protective intervention against alcoholic liver disease. UK NHS alcoholic-liver-disease pathway is alcohol-cessation services + abstinence + (where indicated) hepatology referral. Marketing milk thistle as alcohol-protective is outside trial- evidence boundaries. [7]
Myth""Higher dose milk thistle is more effective for liver disease.""
RealityCochrane review trial-pool dose ranges spanned 280-800 mg/day of standardised silymarin extract without clear dose-response for clinical liver endpoints. Higher doses are not better- evidenced; phytosome / phospholipid-bound preparations achieve substantially better bioavailability than dose increases of standardised extract. [7]
Myth""Milk thistle has no side effects because it's natural.""
RealityAsteraceae allergy is the principal allergy concern (with documented anaphylaxis case reports). Mild GI side effects (laxative effect, nausea, abdominal pain) are documented. Modest CYP / UGT interaction signals warrant disclosure to prescribers. Pregnancy / breastfeeding is contraindicated. Naturalness-as-safety arguments do not apply. [3]
Myth""Milk thistle reverses cirrhosis.""
RealityIt does not. Cirrhosis is a structural change in liver tissue with limited reversibility even with optimal medical care. UK NHS pathway for cirrhosis is hepatology-led, condition- specific, and does not include milk thistle. Marketing implying cirrhosis reversal is outside trial-evidence boundaries. [5]
What people say online
Milk thistle discourse on TikTok and Reddit clusters around four narratives: "liver detox after drinking" (overstated); "natural treatment for fatty liver" (Li 2024 meta-analysis genuinely supportive but UK NICE not adopted); "liver cleanse" wellness marketing (non-regulated framing); and "natural alternative to statins" (mechanism overlap real but not direct clinical equivalence). This section surfaces the discourse without naming individuals.
Trending claims
- TikTok #hangover + r/AskUK + r/cocktailshigh visibility
Claim: Take milk thistle to detox your liver after drinking
Reality check: UK MHRA THR-registered indication is "symptoms associated with occasional overindulgence in food or drink such as indigestion and upset stomach" — a DIGESTIVE indication, not "liver detox". Your liver metabolises alcohol on its own at ~one unit per hour; milk thistle does not accelerate this. The trial evidence (Li 2024 PMID 38579127) is in NAFLD / NASH patients, not in healthy adults after a night out. Best post-drinking advice: hydration, rest, paracetamol / ibuprofen for symptoms (NOT paracetamol if drinking continued). [8]
- TikTok #fattyliver + r/NAFLD + r/Hepatitishigh visibility
Claim: Milk thistle treats fatty liver
Reality check: Li 2024 Ann Hepatol meta-analysis (PMID 38579127, 26 RCTs n=2,375) shows silymarin reduces lipid + liver- enzyme markers and improves histology in NAFLD / NASH. The signal is supportive — but UK NICE NG49 (NAFLD) pathway uses weight management + metabolic-syndrome control as first-line; milk thistle is NOT in the NICE pathway. "Treats" overstates the regulatory and clinical reality. Talk to your GP if you have diagnosed NAFLD before adding. [8]
- TikTok #livercleanse + alternative-medicine Reddithigh visibility
Claim: Liver cleanse / liver detox is essential for everyone
Reality check: "Liver detox" and "liver cleanse" are non-regulated marketing language not authorised under UK NHC register. Your liver clears most metabolites and toxins on its own through normal hepatic phase-I and phase-II conjugation. For healthy adults without diagnosed liver disease, sustained "liver cleanse" supplementation is not a UK NHS-recognised need.
- TikTok + r/Cholesterolmedium visibility
Claim: Milk thistle is the natural alternative to statins
Reality check: Li 2024 meta-analysis shows silymarin reduces LDL-C (SMD -0.81) and total cholesterol (SMD -0.85) in NAFLD patients. Statins reduce LDL-C by 30-55% at standard doses — substantially larger magnitude. UK NICE NG181 (Cardiovascular) and NG28 (T2D) pathways use statins based on QRISK score; replacing prescribed statin with milk thistle is not supported. Milk thistle can be an adjunct conversation with your GP, not a replacement. [8]
Where the conversation lives
- TikTok hashtags: #milkthistle, #livercleanse, #liverhealth, #fattyliver, #hangover, #silymarin
- Reddit subs: r/Supplements, r/NAFLD, r/AskUK, r/Hepatitis, r/AlcoholRecovery
- Forums: British Liver Trust community, Examine.com (paid evidence comparator)
Questions people are searching
- Will milk thistle protect my liver from drinking?
- Does milk thistle treat fatty liver?
- Is milk thistle safe with my prescription medication?
- Standardised extract or whole-seed powder — which?
- Can I take milk thistle in pregnancy?
- Milk thistle or NAC for liver support?
Who drives the discourse: The discourse is driven by four creator classes: hangover / drinking-recovery creators (the alcohol- detox framing — mostly inaccurate); fatty-liver patient creators (the NAFLD treatment framing — Li 2024 meta- analysis supportive but UK NICE not adopted); wellness / detox creators (the "liver cleanse" framing — non-regulated marketing language); and cardiovascular / cholesterol creators (the statin-alternative framing — mechanism overlap real but effect-size dramatically smaller). Verifera editorial does not name individuals.
Social-media trends change quickly. This section is editorial commentary on what people are searching for — not a recommendation.
Common online questions
Synthesised from the questions UK shoppers most often ask online about Milk Thistle (Silybum marianum). Each answer is editorial and links to its evidence in the Sources list below.
I had a heavy weekend — does milk thistle help my liver recover?
UK MHRA THR-registered milk thistle is for occasional digestive overindulgence symptoms. There is no trial-evidenced liver-recovery effect from a single course of milk thistle. The liver recovers from acute alcohol exposure on its own timescale (hours to days for transient enzyme elevation, longer for sustained / heavy exposure). UK NHS guidance on sensible drinking is the longer-term answer. [2]
I have NAFLD — should I take milk thistle?
UK NICE NG49 (Non-alcoholic fatty liver disease) treatment is weight management, metabolic-syndrome control, and (in advanced cases) hepatology referral. Milk thistle is not in the pathway. Some small RCTs in NAFLD have reported modest ALT reductions on milk thistle but this is not a clinical-endpoint result and the Cochrane evidence base is insufficient to support clinical use. Talk to the GP managing your NAFLD. [4]
Can milk thistle replace my hepatitis treatment?
No. UK NHS treatment for hepatitis B and hepatitis C is antiviral therapy via specialist hepatology service. Milk thistle is not a substitute for antiviral treatment and Cochrane evidence does not support its addition to the regimen. If you are on prescribed antiviral therapy and considering milk thistle, disclose to the hepatology team. [6]
I'm taking warfarin — can I take milk thistle?
Disclose to the anticoagulation clinic before starting. Modest in vitro CYP2C9 inhibition signals exist. Clinical anticoagulant interaction is debated and likely modest at standard supplement doses, but the conservative position is disclosure plus monitoring on the first 2-3 INR checks after starting. [13]
Standardised extract or whole-seed powder — which?
For trial-comparable supplementation, standardised extract (70-80% silymarin) or phytosome / phospholipid-bound silybin preparations are what the trial literature uses. Whole-seed milk thistle powder at the same milligram delivers a small fraction of the silymarin content. Read the label for silymarin or silybin percentage.
UK regulatory landscape
UK regulatory tier: Borderline / case-by-case
Milk thistle sits at the food-supplement / Traditional Herbal Medicinal Product (THR) boundary in UK regulation. UK MHRA THR-registered milk-thistle preparations carry the indication "the relief of symptoms associated with occasional overindulgence in food or drink such as indigestion and upset stomach" — based on traditional use, NOT liver-disease treatment evidence. The intravenous silibinin preparation Legalon SIL® is a separate clinical- licence context for hospital pharmacy use in mushroom poisoning. Lower-strength food-supplement-tier milk thistle sold without an MHRA product licence may NOT make any UK health claim — EFSA Article 13 botanical liver claims are on hold. Long history of EU food + supplement use predates 15 May 1997 — NOT a novel food.
What crosses the tier
| Condition | Crosses to |
|---|---|
| Marketing as a liver-disease treatment (NAFLD, hepatitis, cirrhosis, alcoholic liver disease) | |
| Marketing as "liver detox" / "liver cleanse" / "liver flush" | |
| Marketing as alcohol-protection or alcohol-recovery aid | |
| Whole-seed milk thistle sold with trial-evidenced silymarin dose marketing | |
| Marketing without Asteraceae allergy + CYP-interaction disclosure |
Permitted claims
UK MHRA THR-registered milk-thistle products carry the indication "for the relief of symptoms associated with occasional overindulgence in food or drink such as indigestion and upset stomach" — DIGESTIVE symptomatic relief, NOT liver-disease treatment. NO Article 13.1 health claim is authorised; EFSA evaluations on hold. Generic factual description for food-supplement-tier preparations is permitted.
Cross-jurisdiction note
Milk thistle is widely used across the EU, UK, North America, and Asia. UK MHRA THR framework + EMA HMPC monograph apply across the EU. US FDA classifies as dietary supplement under DSHEA with no specific health claim authorisation. Health Canada has a Natural Health Product registration framework with specific Silybum marianum monographs. The intravenous Legalon SIL® preparation is licensed for clinical use in mushroom (Amanita phalloides) poisoning across multiple jurisdictions.
UK regulatory rules evolve. This summary is editorial — businesses should consult regulatory counsel; consumers should consult their pharmacist or GP.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Chronic liver disease (alcoholic, viral hepatitis B / C, non-alcoholic fatty liver disease)
InsufficientEvidenceinsufficientCochrane review (Rambaldi 2007, CD003620.pub3) and subsequent meta-analyses concluded the evidence base for milk thistle in chronic liver disease is insufficient to support clinical use — trial sizes small, durations short, outcome measures heterogeneous, and study-quality limitations. Some RCTs in NAFLD have reported modest reductions in ALT / AST liver enzymes; others have shown no effect. UK NICE liver-disease pathways do not include milk thistle. UK NHS treatment is condition-specific (alcohol cessation, antiviral therapy, metabolic-syndrome control). [7,4,14,15]
Indigestion and digestive discomfort (THR-registered indication)
LimitedEvidencelimitedUK MHRA THR registration covers "the relief of symptoms associated with occasional overindulgence in food or drink". Trial evidence specifically for this indication is small; registration rests on traditional use, not efficacy evidence. The cholagogue (bile-flow-promoting) mechanism is the basis.
Death-cap mushroom (Amanita phalloides) poisoning — INTRAVENOUS silibinin
ModerateEvidencemoderateIntravenous silibinin (Legalon SIL®) is used in clinical protocols for Amanita phalloides poisoning, supported by observational registry and case-series data (controlled trials are not ethically feasible). This is a hospital-pharmacy clinical indication, NOT a food-supplement context. Mechanism: silibinin inhibits OATP1B1 / OATP1B3 transporters, reducing α-amanitin uptake into hepatocytes. Oral milk thistle supplementation does NOT deliver this effect and is not a substitute for emergency hospital care. [16,17]
Type 2 diabetes — adjunctive use
LimitedEvidencelimitedSmall RCTs in type 2 diabetes have reported modest reductions in HbA1c with silymarin supplementation. UK NICE NG28 (type 2 diabetes management) does not include milk thistle. Theoretical hypoglycaemic effect warrants disclosure to the diabetes team if added to existing diabetes medication. [18]
Cancer adjunct — chemotherapy hepatotoxicity protection
InsufficientEvidenceinsufficientLimited trial evidence for milk thistle as a chemotherapy- hepatotoxicity-protective adjunct (Ladas 2010 in paediatric ALL). UK NICE oncology pathways do not include milk thistle. Talk to the oncology team before adding any supplement during chemotherapy — silymarin has CYP / UGT modulation signals that may interact with chemotherapy metabolism.
Effect matrix — per-condition evidence
Per-outcome summary of the published trial corpus: dose ranges studied, duration, evidence grade, and direction of effect. Each row is a citable claim.
| Outcome | Population | Dose | Duration | Evidence | Direction | Sources |
|---|---|---|---|---|---|---|
| Non-alcoholic fatty liver disease (NAFLD) — biochemical markers | adults | 140–800 mg | 8–48 wk | ModerateEvidencemoderate | improvement | PMID 38579127 PMID 33418491 PMID 38505782 PMID 40221681 PMID 36159792 |
| Li 2024 meta-analysis 26 RCTs n=2,375. Silymarin significantly reduced ALT (SMD -12.4 IU/L), AST (SMD -11.0 IU/L), total cholesterol (SMD -0.85), triglycerides (SMD -0.62), LDL-C (SMD -0.81), fasting insulin (SMD -0.59), HOMA-IR (SMD -0.37); increased HDL-C (SMD 0.46). UK NICE NG49 NAFLD pathway does NOT recommend silymarin — lifestyle modification remains first-line. | ||||||
| NAFLD / NASH histological improvement (hepatic steatosis) | adults | 140–800 mg | 24–48 wk | LimitedEvidencelimited | improvement | PMID 38579127 |
| Li 2024 reported OR 3.25 for improved hepatic steatosis on histology (subset of trials reporting histological outcome). LIMITED grade because histology was reported in a smaller trial subset than biochemical markers and biopsy methodology varied. | ||||||
| Cirrhosis / chronic liver disease mortality | adults | — | — | InsufficientEvidenceinsufficient | no change | — |
| Older Cochrane Rambaldi 2007 review of milk thistle in chronic liver disease found insufficient evidence to support clinical use for mortality / decompensation endpoints. Cited as historical context in body-text; Rambaldi 2007 not in body-text PMID set so citations empty. This row exists to balance the contemporary positive Li 2024 NAFLD signal against the older cirrhosis-mortality negative. | ||||||
| Acute amanita mushroom poisoning (IV silibinin) | general | — | — | LimitedEvidencelimited | improvement | — |
| IV silibinin is a hospital antidote in death-cap (Amanita phalloides) mushroom poisoning. NOT relevant to oral consumer milk thistle. Listed only to acknowledge the clinically distinct use of the silibinin compound; should NOT be conflated with consumer-product effect_matrix rendering. Recommend sizar drops this row if rendering surface confuses readers. | ||||||
Evidence grades follow the editorial convention: strong > moderate > limited > very_limited > insufficient. Direction reports the trial corpus consensus (improvement / no_change / mixed / decrement). Schema cross-emitted at MedicalSubstance.relevantClinicalCondition[].
Clinical literature review
The milk thistle literature splits across three threads: contemporary NAFLD / NASH meta-analyses showing improvement in biochemical liver markers (Li 2024 Ann Hepatol PMID 38579127 26 RCTs n=2,375 — strongest contemporary signal); older Cochrane reviews (Rambaldi 2007) of chronic liver disease finding insufficient evidence to support clinical use; and case-series + traditional-use evidence underpinning the UK MHRA THR registration for digestive symptomatic relief. UK NICE NG49 (NAFLD), CKS Hepatitis pathways do NOT include milk thistle.
Key trials
Li S, Duan F, Li S, Lu B · 2024 · Ann Hepatol · PMID 38579127
Finding: Silymarin (the active flavonolignan complex in milk thistle) significantly reduced total cholesterol (SMD -0.85), triglycerides (SMD -0.62), LDL-C (SMD -0.81), fasting insulin (SMD -0.59), and HOMA-IR (SMD -0.37); increased HDL-C (SMD 0.46). Attenuated liver injury with significant reductions in ALT (SMD -12.4 IU/L) and AST (SMD -11.0 IU/L). Reduced fatty liver index and fatty liver score. Liver histology in intervention group showed significantly improved hepatic steatosis (OR 3.25, 95% CI 1.80-5.87). Authors conclude silymarin "can regulate energy metabolism, attenuate liver damage, and improve liver histology in NAFLD patients" — pending further confirmation.
Relevance: The most recent and largest meta-analysis of silymarin in NAFLD / NASH. Supportive contemporary signal across multiple biomarkers + improved histology. Effect sizes are modest but consistent. UK NICE NG49 (NAFLD) pathway has NOT adopted silymarin / milk thistle despite the meta-analytic signal; pathway remains weight management + metabolic-syndrome control.
Systematic reviews
- pmid:38579127
Li 2024 Ann Hepatol — 26 RCTs n=2,375, silymarin in NAFLD/NASH significantly reduced lipid markers (TC, TG, LDL-C) + liver enzymes (ALT, AST) + improved hepatic steatosis on histology. Contemporary supportive meta-analytic signal.
Evidence quality summary
NAFLD / NASH biochemical-marker improvement — MODERATE certainty (Li 2024 PMID 38579127 — 26 RCTs n=2,375 consistent multi-marker signal). NAFLD / NASH histological improvement — LIMITED-to-MODERATE certainty (Li 2024 OR 3.25 for improved hepatic steatosis). UK NICE NG49 pathway inclusion — NONE despite the meta-analytic signal. Older chronic liver disease (alcoholic, viral hepatitis) Cochrane review — INSUFFICIENT historical evidence (Rambaldi 2007 superseded by more recent meta-analyses but the pathway has not changed). UK MHRA THR-registered indication (digestive symptomatic relief) — based on traditional use. Asteraceae cross-reactivity safety — HIGH certainty.
Known gaps
- UK / NHS-population RCT of silymarin in NAFLD against UK NICE NG49 standard care.
- Direct head-to-head comparison of standardised silymarin vs phytosome / phospholipid-bound silybin preparations.
- Long-term outcomes data (>1 year) for silymarin in NAFLD progression.
- Adoption pathway by UK NICE for silymarin in NAFLD (Li 2024 meta-analysis evidence not yet reflected in NG49).
This summarises the published evidence as of the last review date — it is not advice for your specific situation. Talk to your pharmacist or GP.
Safety
Milk thistle is generally well-tolerated for adults without Asteraceae allergy at standard supplement doses for short-to- medium-term use. The realistic considerations are Asteraceae- family allergy (cross-reactive with ragweed, daisy, marigold, chamomile, echinacea), modest CYP / UGT interaction signals, pregnancy avoidance, and the strong "do not stack with active hepatitis or cirrhosis treatment without hepatology input" rule.
Talk to your pharmacist or GP first if you:
- You have a documented allergy to ragweed, daisy, mugwort, marigold, chamomile, echinacea, or feverfew — Asteraceae cross-reactivity.
- You take warfarin or another anticoagulant — modest CYP2C9 signals; disclose to anticoagulation clinic.
- You take a chemotherapy drug — silymarin has CYP / UGT signals that may interact; disclose to oncology team.
- You take an oral diabetes medicine — theoretical hypoglycaemic effect; monitor glucose.
- You take a CYP3A4-metabolised medication (statins, calcium-channel blockers, certain antidepressants) — modest CYP signals; disclose to prescriber.
- You have diagnosed chronic liver disease — talk to the hepatology team before starting.
- You are pregnant or breastfeeding — avoid concentrated extracts.
Common side effects: Generally well-tolerated. Mild laxative effect, nausea, abdominal pain. Allergic reactions in Asteraceae-sensitised individuals.
Pregnancy and breastfeeding
Avoid concentrated milk-thistle supplement extracts in pregnancy. UK MHRA THR-registered product literature typically lists pregnancy as a contraindication; supplement- tier pregnancy safety is not formally established. Talk to your midwife or GP if uncertain about a specific product.
Avoid concentrated milk-thistle supplement extracts during breastfeeding. Some traditional galactagogue use exists but evidence is limited and supplement-tier safety in lactation is not established. Talk to your midwife or health visitor before adding.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Documented allergy to milk thistle or other Asteraceae plants.
- Pregnancy and breastfeeding for concentrated supplement extracts.
- Hypersensitivity to silymarin.
Drug interactions
CYP2C9-metabolised medications (warfarin, certain NSAIDs, gliclazide, glimepiride, losartan) · medium
Effect: Modest in-vitro CYP2C9 inhibition signals; clinical relevance is debated and likely modest at standard supplement doses, but for warfarin specifically the narrow therapeutic index means even modest CYP2C9 signals warrant anticoagulation-clinic awareness.
Mechanism: Silymarin flavonolignans show in-vitro CYP2C9 inhibition; in vivo clinical translation appears modest at oral supplement doses but is not zero. Warfarin INR is the most sensitive readout.
Action: Tell your anticoagulation clinic if you start a course of standardised silymarin while on stable warfarin; INR should be checked more frequently in the first 2-3 weeks. Tell your diabetes / hypertension / NSAID prescriber if you have ongoing treatment.
Source: BNF CYP-metabolised medicines + UK NICE CKS Anticoagulation - oral
Anti-cancer / chemotherapy agents (irinotecan, methotrexate, tamoxifen, etc.) · medium
Effect: Multiple in-vitro CYP3A4 + CYP2C9 + UGT + OATP1B1/1B3 signals affecting metabolism of common chemotherapy agents. Clinical relevance is debated and trial evidence is sparse, but the potential for altered chemotherapy plasma exposure makes disclosure mandatory.
Mechanism: Silymarin / silibinin shows in-vitro inhibition of multiple drug-metabolism + uptake-transporter pathways relevant to chemotherapy pharmacokinetics. Some signals are the basis for the IV Legalon SIL® mushroom-poisoning indication.
Action: Tell your oncology team about ANY milk thistle / silymarin supplement use BEFORE starting chemotherapy or alongside ongoing treatment. The team may agree continuation, may advise discontinuation, or may adjust monitoring.
Source: BNF anti-cancer agents + UK NICE cancer-specific pathways
CYP3A4-metabolised medications (statins, calcium-channel blockers, certain antidepressants, certain antiretrovirals, sirolimus, tacrolimus, midazolam) — modest in vitro CYP3A4 inhibition signals; clinical relevance debated and likely modest at standard doses.
UGT-metabolised medications (irinotecan SN-38 active metabolite, raloxifene, lamotrigine, lorazepam, morphine, propofol) — modest in vitro UGT signals; disclose to oncology / pain team where relevant.
OATP1B1 / OATP1B3 substrates (statins, methotrexate, fexofenadine) — silibinin is the basis for the IV Legalon SIL® mushroom-poisoning indication via OATP transporter inhibition. Oral supplementation produces modest signal.
Oral diabetes medicines (metformin, sulphonylureas, insulin) — theoretical mild hypoglycaemic effect; monitor glucose if added.
Tell your prescriber if you take any of these combinations. This is not personalised advice.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- Mild laxative effect (silymarin promotes bile flow).
- GI upset — nausea, bloating, abdominal cramping (uncommon).
Rare side effects
- Allergic reactions including urticaria, contact dermatitis, anaphylaxis — Asteraceae-sensitised individuals.
- Headache.
- Insomnia (rare).
- Theoretical hypoglycaemia in diabetes patients on hypoglycaemic medication.
How to take it
- Typical supplemental range
- UK MHRA THR-registered milk thistle preparations typically deliver 80-200 mg/serving of standardised seed extract at 70-80% silymarin (i.e., 56-160 mg silymarin per serving). Cochrane review trial-pool dose range was 280-800 mg/day silymarin. Phytosome / phospholipid-bound silybin preparations (Siliphos®, IdB 1016) deliver substantially better bioavailability and use lower silybin doses (140-280 mg/day).
- Timing
- Daily — split-dose 2-3× daily is most common in trial protocols. Take with food to reduce GI side effects.
How to spot quality
Look for
- Plant species declared as Silybum marianum specifically.
- Standardisation declared: silymarin percentage (typical 70-80%) or silybin / silibinin percentage in the dry extract.
- MHRA THR licence number on the pack ("THR XXXXX/XXXX") for traditional-use registered products.
- Asteraceae-allergy warning visible on the pack.
- Phytosome / phospholipid-bound silybin (Siliphos®, IdB 1016) for better-bioavailability trial-grade material.
- GMP-certified manufacture.
- Heavy-metal screen disclosed on spec sheet (milk thistle is grown widely and accumulates soil contaminants).
Red flags
- No silymarin or silybin percentage declared.
- No MHRA THR licence number on a product positioned for liver-cleansing claims — none of those wordings is authorised in the UK without THR registration, and the THR scope is digestive-discomfort symptomatic relief, NOT liver disease.
- Marketing as "liver cleanse" / "liver flush" / cleansing-tier liver positioning — outside UK rules and outside trial-evidence boundaries.
- Marketing for hepatitis treatment, cirrhosis reversal, or fatty-liver-disease cure — outside UK NHS pathway.
- No Asteraceae-allergy warning.
- Marketing milk thistle as "natural alcohol protection" — outside trial-evidence boundaries.
Where Camden lands · meets the bar
Camden Medicals does not currently retail a single-active milk- thistle SKU. The Verifera editorial position is that UK MHRA THR-registered preparations (Silymarinum, Silybonol, similar) with declared silymarin standardisation (typically ≥70 % silymarin flavonolignan content) are the appropriate tier for digestive-discomfort symptomatic relief. The "liver cleanse" marketing framing common in lower-tier products is outside both UK THR scope and trial-evidence boundaries — Camden's editorial position rejects that framing on principle. Entry conditions for any future Camden milk-thistle SKU: declared silymarin % (silybin / isosilybin / silydianin / silychristin); declared bioavailability-enhanced form where applicable (silymarin-phosphatidylcholine complex, e.g. Siliphos, has 7-10× higher bioavailability than standard silymarin); MHRA THR registration for any cold / digestive indication on label; Asteraceae-allergy warning visible; heavy-metal screen on spec sheet.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
N-Acetyl Cysteine (NAC)
Limited evidenceThe classic liver-cluster pairing — silymarin antioxidant and membrane-stabilising mechanism plus NAC glutathione-precursor mechanism for hepatic oxidative-stress framing.
Silymarin acts on hepatocyte oxidative stress through scavenging reactive oxygen species and modest NF-κB modulation. NAC (N-acetylcysteine) is a precursor to glutathione (the principal intracellular antioxidant), providing the cysteine substrate for glutathione synthesis in hepatocytes. The two mechanisms are complementary on the hepatic-antioxidant axis — silymarin on the membrane / direct-radical-scavenging side, NAC on the glutathione-substrate side.
NAC has substantially stronger clinical-trial evidence than milk thistle — most notably as the hospital-pharmacy intravenous treatment for paracetamol overdose where it is the standard-of-care antidote. Oral NAC supplementation has its own trial body for chronic respiratory conditions (mucolytic effect) and has been studied in NAFLD and hepatic fibrosis with modest signals.
The combination is mechanism-additive but trial evidence specific to the combined regimen on liver endpoints is limited. UK NHS pathways for chronic liver disease do not include either as a routine intervention; both are food-supplement-tier in the consumer market.
Evidence: Mechanism complementary on hepatic oxidative-stress axis. NAC hospital-pharmacy paracetamol indication is well-established; oral NAC supplementation has its own modest trial body. Combined regimen trial evidence on liver endpoints is limited.
Doses studied: Milk thistle standardised extract 200-600 mg/day (140-480 mg silymarin) + NAC 600-1200 mg/day. NB-435 NAC covers the NAC component.
Found in Camden: Purifera™ NAC N-Acetyl-Cysteine 600mg 120 Capsules
Turmeric (Curcuma longa)
Limited evidenceLiver and anti-inflammatory cluster pairing — silymarin and curcumin both have NF-κB-modulating mechanism, with overlapping but not identical trial bodies for chronic-liver-disease and inflammatory-condition use.
Both silymarin and curcumin (the principal active in turmeric, Curcuma longa) inhibit NF-κB signalling in cell-biology assays. Both have modest trial bodies in NAFLD with mixed results on ALT / AST liver enzymes. Both share the bioavailability problem — oral absorption of free curcumin and silymarin is limited; phospholipid-bound preparations (Meriva® curcumin phytosome, Siliphos® silybin phytosome) substantially improve absorption.
The combination appears in many UK liver-cluster supplements alongside black pepper (piperine) for absorption enhancement and (sometimes) NAC. Trial evidence specific to the combination is limited; each component has its own trial body. UK NICE does not include either in liver-disease pathways.
Evidence: Mechanism complementary on NF-κB axis. Trial evidence for each component is mixed. Combination trials are essentially absent.
Doses studied: Milk thistle standardised extract 200-400 mg + turmeric standardised extract 500-1000 mg (95% curcuminoids) + black pepper 5-10 mg (piperine), 2× daily with food.
Ginger (Zingiber officinale)
Limited evidenceDigestive-cluster pairing — both feature in dyspepsia / overindulgence-relief herbal preparations, on different mechanisms.
Silymarin has mild cholagogue (bile-flow-promoting) activity — the basis for the THR-registered digestive-discomfort indication. Ginger acts on gastric motility and 5-HT3 receptor antiemetic signalling. The combination is mechanism-complementary across two GI axes.
The combination appears in some THR-registered digestive products and in functional-dyspepsia herbal preparations. Trial evidence specifically for the combination is limited.
Evidence: Mechanism complementary across bile-flow and motility axes. Combination trials limited.
Doses studied: Milk thistle 200-400 mg + ginger 250-500 mg, 2-3× daily with meals or evening, particularly after rich-food / alcohol exposure.
Black Pepper (Piper nigrum)
Limited evidenceAbsorption-enhancement adjunct — piperine inhibits hepatic glucuronidation and may improve silymarin and silybin oral absorption, though evidence is debated.
Piperine (the alkaloid that gives black pepper its characteristic heat) inhibits intestinal and hepatic glucuronidation (UGT enzymes), reducing first-pass conjugation of silymarin and silybin and theoretically improving their systemic bioavailability. Piperine also inhibits CYP3A4 and P-gp.
The combination is asymmetric — piperine''s role here is purely a delivery enhancer, not the reverse. Piperine-enhanced silymarin trial evidence is small. Phytosome / phospholipid-bound silybin preparations (Siliphos®) achieve substantially better bioavailability through a different mechanism (phospholipid carrier) and are the more-trialled bioavailability route.
Evidence: Mechanism plausible (UGT inhibition); direct combination trials small. Phytosome preparations are the more-trialled bioavailability route.
Doses studied: Milk thistle 200-400 mg + black pepper 5-10 mg standardised to ≥95% piperine (BioPerine®). Camden does not endorse this combination as a primary intervention; Siliphos® phytosome is the better-trialled bioavailability route.
Verifera™ editorial perspective
Why it matters. Milk thistle is one of the highest-traffic UK liver-support botanicals, dominated by "liver detox" / "liver cleanse" marketing that does NOT match the actual UK regulatory tier (THR digestive symptomatic indication, NOT liver-disease treatment) or the contemporary evidence base. The Li 2024 meta-analysis (PMID 38579127) provides a genuinely supportive contemporary signal in NAFLD biomarkers but UK NICE pathway has not adopted. The Verifera editorial position is to keep the regulatory + clinical reality front-and-centre and honestly anchor consumers in the UK NHS pathway for diagnosed liver disease.
Where Camden lands. Camden Medicals does NOT currently retail single-active milk-thistle SKUs. The entry serves as the Asteraceae liver-cluster reference alongside Camden's echinacea + elderberry entries. For UK consumers researching this space: a UK MHRA THR-registered silymarin-standardised product is the controlled-quality route; whole-seed powder is not trial-comparable; Asteraceae allergy is a hard contraindication. For diagnosed liver disease (NAFLD, alcoholic liver disease, hepatitis), UK NICE pathway (lifestyle + weight management + condition-specific medication) is the foundation; milk thistle is an optional adjunct conversation with your GP / hepatology team, not a replacement.
If you want to explore further. If you don't have diagnosed liver disease: there is no compelling case for milk thistle supplementation. Sustained "liver cleanse" framings are non-regulated marketing language; your liver clears most things on its own. If you do have diagnosed NAFLD / alcoholic liver disease / hepatitis: UK NICE NG49 (NAFLD) + condition-specific pathways come first. Milk thistle as an adjunct: standardised silymarin extract (≥70-80% silymarin or silybin declared on label) at trial-evidenced dose (typically 200-420 mg silymarin / day) for 8-12 weeks; talk to your GP / hepatology team about your specific clinical context. Asteraceae allergy: do not take milk thistle.
How this entry was researched
Authoritative sources consulted:
- NHS Alcohol-related liver disease + Non-alcoholic fatty liver disease pages
- NICE NG49 (NAFLD) + CKS Hepatitis + NG181 (Cardiovascular)
- MHRA Traditional Herbal Registrations register (silymarin / milk thistle preparations)
- BHMA Herbal Compendium (Silybum marianum)
- EMA HMPC Silybum marianum community monograph
- GB Nutrition and Health Claims (NHC) Register (no authorised milk-thistle claim outside MHRA THR)
- British Liver Trust patient information resources
- Cochrane Database (Rambaldi 2007 and updates) on milk thistle for chronic liver disease
- PubMed (via E-utilities MCP, 2026-05-12)
PubMed search terms:
silymarin milk thistle liver disease NAFLD systematic review meta-analysis
Literature search date: 2026-05-12
Sources listed are those consulted by the Verifera™ editorial team. Readers should verify against current authoritative sources.